LivaNova (NASDAQ:LIVN) Hits New 1-Year Low – Here’s What Happened

LivaNova PLC (NASDAQ:LIVN)’s stock price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $40.03 and last traded at $40.02, with a volume of 70886 shares changing hands. The stock had previously closed at $40.87.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. The Goldman Sachs Group decreased their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a report on Monday. Stifel Nicolaus decreased their price target on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Mizuho decreased their price target on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Finally, Needham & Company LLC reduced their target price on LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $62.20.

LivaNova Trading Down 3.2 %

The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The company has a fifty day simple moving average of $47.08 and a 200-day simple moving average of $49.43. The company has a market capitalization of $2.15 billion, a PE ratio of 94.10 and a beta of 1.10.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On LivaNova

Several hedge funds have recently bought and sold shares of LIVN. Point72 Asset Management L.P. lifted its stake in LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after acquiring an additional 806,374 shares during the last quarter. Freestone Grove Partners LP acquired a new stake in shares of LivaNova in the 4th quarter valued at $23,102,000. Artisan Partners Limited Partnership purchased a new stake in shares of LivaNova during the 4th quarter worth $21,340,000. The Manufacturers Life Insurance Company grew its stake in shares of LivaNova by 163.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company’s stock worth $25,303,000 after purchasing an additional 339,139 shares in the last quarter. Finally, AQR Capital Management LLC increased its holdings in LivaNova by 79.3% in the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company’s stock valued at $34,214,000 after buying an additional 328,313 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.